Ascentage Pharma presented clinical data on alrizomadlin (APG-115), an MDM2-p53 inhibitor, for treating pediatric solid tumors at ASCO 2026. The drug showed preliminary antitumor activity with manageable safety profiles as monotherapy and in combination with lisaftoclax, achieving a 23.5% objective response rate in the combination arm. Alrizomadlin was included in China's SPARK Plan for pediatric oncology development.

Ascentage Pharma announced Phase Ib study results showing olverembatinib combined with blinatumomab demonstrated encouraging clinical activity in patients with relapsed/refractory Ph+ BCP-ALL or CML-LBP, with 91% achieving complete response and manageable safety profile. The company presented six studies across three key assets at the 2026 ASCO Annual Meeting, marking its ninth consecutive appearance.

Ascentage Pharma presented updated clinical data at ASCO 2026 showing olverembatinib achieved a 91.3% complete cytogenetic response rate and 60.9% major molecular response rate at cycle 24 in CML-CP patients as second-line therapy. The drug demonstrated a stable safety profile with no new safety signals, supporting its potential role in treating patients who failed first-line TKI therapy.

Ascentage Pharma Group International announced that 17 clinical advances of its core assets, including 8 poster presentations, will be featured at the 31st Congress of the European Hematology Association (EHA2026) in Stockholm from June 11-14, 2026. The presentations showcase data from ongoing clinical studies of Olverembatinib (HQP1351), China's first approved third-generation BCR-ABL inhibitor, and Lisaftoclax (APG-2575), the first approved China-developed Bcl-2 selective inhibitor, across various hematologic malignancies and leukemia indications.

Ascentage Pharma announced that six abstracts from clinical studies of three key drug candidates have been selected for presentation at the 2026 ASCO Annual Meeting, including three rapid oral presentations and three poster presentations. The presentations will showcase data on Olverembatinib (HQP1351), Lisaftoclax (APG-2575), and Alrizomadlin (APG-115) across various cancer indications. This marks the company's ninth consecutive year presenting at ASCO.

Ascentage Pharma reported 2025 product sales and commercial rights revenues increased 90% year-over-year to US$82.1 million, driven by Olverembatinib sales growth of 81% to US$62.2 million and new Lisaftoclax sales of US$10.1 million following its July 2025 launch in China. The company is advancing nine registrational Phase III clinical trials globally, with four cleared by FDA and EMA. Despite strong commercial progress, the company reported a net loss of US$177.7 million for 2025.

Ascentage Pharma announced it will release its full year 2025 unaudited financial results and business updates on March 25, 2026, with separate English and Mandarin language investor webcasts. The company, a global biopharmaceutical firm focused on cancer therapies, has two approved products (Olverembatinib and Lisaftoclax) and is conducting multiple Phase III clinical trials.

Ascentage Pharma Group International announced that its novel BTK-targeted protein degrader APG-3288 has received IND clearance from both the U.S. FDA and China CDE, enabling clinical studies in patients with relapsed/refractory hematologic malignancies. The drug uses PROTAC technology to degrade BTK rather than inhibit it, potentially overcoming resistance to existing BTK inhibitors. This milestone strengthens the company's pipeline in hematologic malignancies alongside its approved products Olverembatinib and Lisaftoclax.

Ascentage Pharma presented its global innovation strategy at the J.P. Morgan Healthcare Conference, highlighting progress with two commercialized hematology products (Olverembatinib and Lisaftoclax) and announcing FDA IND clearance for next-generation BTK degrader APG-3288. The company is advancing multiple Phase III registrational trials and expects significant milestones in 2026 across commercialization, clinical development, and early-stage programs.

Ascentage Pharma received FDA IND clearance for APG-3288, a novel BTK-targeted protein degrader using PROTAC technology, to treat relapsed/refractory B-cell malignancies. The drug is designed to degrade BTK proteins rather than inhibit them, potentially overcoming resistance to existing BTK inhibitors and representing a major pipeline expansion for the company.

Ascentage Pharma presented four-year follow-up data for Olverembatinib, demonstrating improved disease control and safety in treating chronic myeloid leukemia patients resistant to existing tyrosine kinase inhibitors.

Ascentage Pharma presented promising Phase III study results for Olverembatinib in treating Philadelphia chromosome-positive acute lymphoblastic leukemia, showing a 66% minimal residual disease negativity rate and favorable safety profile.